Hematopoietic cell transplantation beyond first remission.
Appelbaum
F R
FR
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA.
D000208:Acute Disease; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D015897:Comorbidity; D016572:Cyclosporine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009679:Nuclear Family; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D016572:Cyclosporine; D008942:Mitoxantrone; D014740:Vidarabine; C024352:fludarabine; D003630:Daunorubicin